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ABSTRACT   
Congenital disorders of glycosylation (CDG) are a group of genetic diseases caused by 
hypoglycosylation of proteins and lipids. Confirmation of clinical diagnosis relies on 
enzymatic studies in leukocytes, lipid-linked oligosaccharide (LLO) analysis in fibroblasts 
and MALDI-TOF spectrometry, followed by molecular genetic analysis. CDG are associated 
with a broad-spectrum clinical features, ranging from paucisymptomatic individuals to 
extremely severe phenotypes with multi-organ involvement. Epilepsy is commonly observed 
in CDG, often as an early manifestation, but no distinctive epilepsy phenotypes are 
recognised. 
We described four children (three girls, one boy) with CDG who were first referred between 
the 1st and 4th month of life, after onset of epilepsy, soon manifested as an epileptic 
encephalopathy with migrating partial seizures. All patients eventually manifested 
developmental delay, microcephaly and multiorgan involvement. MRI disclosed cerebral and 
cerebellar atrophy. Isoelectrofocusing of transferrin (TIEF), enzymatic studies, lipid-linked 
oligosaccharide (LLO) analysis and spectrometry strongly indicated CDG-I. Genetic testing 
demonstrated either homozygous or heterozygous variants involving the ALG3 gene in 
patient 1 [homozygous: NM_005787.5:c.1A>G p.(Met1?)] and 3 [compound heterozygous: 
NM_005787.5: c.l061G>A p.(Arg354His) and NM_005787.5:c.165C>T p(.Gly55Gly)], the 
RFT1 gene in patient 2 [homozygous: NM_052859.3:c.454A>G p.Lys152Glu)] and of the 
ALG1 gene in patient 4 [compound heterozygous: NM 019109.4: c.773C>T p.(Ser258Leu) 
and NM 019109.4: c.866A>T p.(Asp289Val)]. At last follow up, patients 1 and 2 were 5 and 
3.5 years old. Patients 3 and 4 had died due to respiratory failure at age 6 years and refractory 
status epilepticus at age 1 year.  Migrating partial seizures in infancy are etiologically 
heterogeneous. Concomitant multisystem involvement should prompt investigations for 
CDG. 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INTRODUCTION (1300 words) 
Congenital disorders of glycosylation (CDG) are a group of genetic diseases caused by 
hypoglycosylation of proteins and lipids. Since their first description in 1980 several protein 
N- and O-glycosylation defects have been identified.1–4 Isoelectrofocusing of transferrin 
(TIEF) is the screening test for N-glycosylation defects while isoelectrofocusing of 
apolipoprotein C-III (ApoC-III) is utilised to detect O-glycan synthesis disorders.1,2 Based on 
the TIEF pattern, protein N-glycosylation disorders have been subdivided into two groups: 
CDG-I caused by defects in the assembly of glycans and their attachment to proteins 
(occurring in the cytosol and the endoplasmic reticulum), and CDG -II caused by defects in 
the processing of the glycans (in the endoplasmic reticulum and the Golgi).1,2  
Confirmation of clinical diagnosis relies on enzymatic studies in leukocytes, lipid-linked 
oligosaccharide (LLO) analysis in fibroblasts and MALDI-TOF spectrometry followed by 
molecular analysis to detect underlying gene defects.2    
Impaired glycosylation is associated with a wide range of clinical manifestations ranging 
from paucisymptomatic individuals to extremely severe phenotypes with multi-organ 
involvement 1,2 As a consequence of their phenotypic variability, CDG represent a diagnostic 
challenge and are still largely under-diagnosed.   
Epilepsy is commonly observed in CDG and is often a presenting symptom. Although 
infantile spasms, focal and generalised seizures are often mentioned,1–3 no distinctive 
epilepsy phenotype is recognised. Identification of a characteristic presentation may help 
early diagnosis.  
We report on four children with CDG and migrating partial seizures, describe their clinical 
course, electrographic, imaging, biochemical and genetic findings and suggest that CDG be 
considered in the differential diagnosis of disorders manifested as early EE with migrating 
partial seizures.   
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METHODS 
Based on the initial observation of an index case with migrating partial seizures, in whom we 
diagnosed CDG due to associated microcephaly, facial dysmorphisms, spastic quadriparesis, 
and severe cognitive impairment (patient 1, Table 1), we investigated whether this epilepsy 
phenotype pattern was a recurrent presentation of the disorder. We then evaluated a cohort of 
16 additional children with CDG followed in three tertiary Pediatric Neurology Centers 
(Children’s Hospital A. Meyer, Florence; Bambino Gesù Children’s Hospital, Rome; Verona 
University Hospital) and analysed clinical course, biochemical and genetic findings, EEG and 
imaging features. Additional information on genetic testing is summarized in Supplementary 
Methods. 
The ethical committee of Tuscany Region, Italy approved the study. Informed consent was 
obtained for all patients.  
RESULTS 
Clinical, EEG and neuroimaging findings  
Four of 17 consecutively observed children with CDG had manifested migrating partial 
seizures as an early feature.  There were three girls (patients 2-4) and one boy (patient 1); at 
last follow-up,  patients 1 and 2 were 5 and 3.5 years old while patients 3 and 4 had died due 
to respiratory failure and refractory status epilepticus, respectively. All patients exhibited 
developmental delay, microcephaly and multiorgan involvement.  
Migrating seizures appeared between the 1st and 4th month of life, involving clinically and 
electrographically either side, occurring in repeated clusters, with prominent clonic or tonic 
manifestations (Figure 1). In patients 1 and 4, partial seizures were at times accompanied by 
spasms.  
MRI disclosed cerebral and cerebellar atrophy in all patients (Figure 2).  
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Additional clinical information on the four patients is summarised in Table 1. 
Biochemical and genetic studies (Table 1) 
Metabolic screening (blood and cerebrospinal fluid [CSF] lactate, pyruvate and glucose, 
quantitative plasma and CSF amino acids, quantitative urine organic acids, plasma 
acylcarnitine profile, neurotransmitters) was normal in all patients.  
Array-CGH and targeted re-sequencing of a panel of 95 epilepsy related genes were negative 
in three children (1-3).  
TIEF indicated CDG I in all four patients. Enzymatic studies, lipid-linked oligosaccharide 
(LLO) analysis and spectrometry confirmed the diagnosis in three tested children (1-3). In the 
remaining patient (4) these analyses were not performed.  
In patient 1, a new homozygous variant [NM_005787.5:c.1A>G p.(Met1?)] was identified in 
the ALG3 gene using a 25 CDG I gene panel and subsequently confirmed by Sanger 
sequencing. Bioinformatic analysis predicted the amino acid substitution to be probably 
pathogenic (Polyphen2 score: 0.713, Mutation Taster score: 1, SIFT score: 0.00). In patient 2, 
a homozygous variant in the RFT1 gene [NM_052859.3:c.454A>G p.(Lys152Glu)] was 
detected by whole exome sequencing (WES) and confirmed by Sanger sequencing. This 
variant was previously described as causative5. Patient 3 was compound heterozygous for two 
variants in the ALG3 gene [NM_005787.5:c.l061 G>A p.(Arg354His) and NM_005787.5:c.
165C>T p.(Gly55Gly)] as demonstrated using a 79 CDG I, II and congenital muscular 
dystrophy-dystroglycanopathy genes panel, and confirmed by Sanger sequencing.  The new 
variant c.l061 G>A p.(Arg354His) was predicted to be pathogenic (Polyphen2 score: 1, 
Mutation Taster score: 1, SIFT score: 0.00). p.Arg354 is a phylogenetically conserved 
aminoacid mapping in an ALG3 loop, which protrudes to the cytosolic side of the 
endoplasmic reticulum membrane6. A disease-causing variant in the same codon 
[NM_005787.5:c.1060C>T p.(Arg354Cys)] was previously reported.7 The synonymous 
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variant c.165 C>T in the ALG3 gene has been reported to affect splicing.8 Patient 4 was 
compound heterozygous for two variants in the ALG1 gene [NM_019109.4:c.773C>T p.
(Ser258Leu) and NM_019109.4:c.866A>T p.(Asp289Val)] as demonstrated using a 79 CDG 
I, II and congenital muscular dystrophy-dystroglycanopathy genes panel, and confirmed by 
Sanger sequencing. The variant p.(Ser258Leu) was previously reported as causative.9 The 
new variant p.(Asp289Val) in ALG1 was predicted to be pathogenic (Polyphen2: score 1, 
Mutation Taster score: 1, SIFT score: 0.00). p.Asp289 is a highly conserved aminoacid and 
there is a large physiochemical difference between Asp and Val.  
Parents of all children were asymptomatic heterozygous carriers of the segregating familial 
variants. 
DISCUSSION 
Epilepsy is commonly observed in infants with CDG. Infantile spams, generalised and focal 
seizures have been variably reported1–3, but no distinctive epilepsy phenotype has been 
identified. 1–3  
Migrating partial seizures of infancy are considered to be a distinctive phenotype and the 
hallmark of a severe form of early onset epileptic encephalopathy (MPSI also known as 
EIEE14, OMIM: #614959)10,11, now recognised as a new syndrome entity12 (Epilepsy of 
infancy with migrating focal seizures - EIMFS).13 . EIMFS has been associated with variants 
of different genes (SCN1A, SCN8A,PLCB1, KCNT1,SCN8A, SLC25A22,QARS, TBC1D24, 
SLC12A5)11,13,14 and with 16p11.2 duplication.15 
KCNT1 gene mutations are the most frequent genetic cause of EIMFS11 and have been 
associated with a particularly pharmacoresistant migrating partial seizures, arrest of 
psychomotor development, and normal MRI at onset.11,14  
In our patients, migrating partial seizures were part of a complex clinical picture 
characterised by early developmental delay, quadriparesis, microcephaly, dysmorphic facial 
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features, multi-organ involvement and accompanied cerebral and cerebellar atrophy as 
demonstrated by MRI. Biochemical and spectroscopy prompted by the above clinical features 
led us to the diagnosis of CDG which was genetically confirmed in all patients. We could not 
find co-occurring abnormality in any of the genes previously associated with EIFMS.11,13,14   
CDG pose considerable diagnostic challenges, due to their high phenotypic variability, and 
should be ruled out in any unexplained clinical condition in which multiorgan dysfunction is 
associated with neurological involvement.3 Limited awareness of CDG is the main reason 
why they are still under-diagnosed.1  
Our findings suggest that in children with EE with migrating partial seizures, concomitant 
multisystem involvement should prompt investigations for CDG. 
The association of CDG and migrating partial seizures represents a form of early onset 
genetic EE due to an 'interposed' structural abnormality.12 Neuropathological studies of the 
whole brain in CDG has revealed loss of Purkinje and granule cells, white matter depletion in 
the cerebellum, and neuronal loss in pontine nuclei, inferior olives and cerebral cortex.16,17 
Widespread brain damage and the important role of glycans in cell–cell interactions and 
intracellular signalling1,3 might explain seizure onset from multiple brain sites in a same 
individual.  
In this study, two patients (1 and 3) harboured causative ALG3 variants, one (Patient 2) a 
causative RFT1 variant and one (Patient 4) a causative ALG1 variant (Patient 3).  Our patients 
exhibited most of the general clinical features described in previous reports on the above 
mentioned CDG.1,2  
Further studies including a greater number of patients with CDG might identify more precise 
correlations between genotype and the epilepsy phenotype.  
“Supplementary information is available at European Journal of Human Genetics  website” 
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Titles and legends to figures  
Figure 1: Ictal EEG accompanying migrating partial seizures in the four patients. Arrows 
indicate seizure onset. (A) Patient 1: Left parieto-occipital (red arrow), right fronto-central 
(red arrowheads) and right temporo-occipital (black arrow) ictal activity. (B) Patient 2: Left 
fronto-centro-temporal and vertex (red arrows), left parieto-occipital (red arrowhead) and 
right fronto-central (black arrows) ictal activity. (C) Patient 3: Right centro-parietal (red 
arrow), right temporal (black arrow) and vertex (red arrowhead) ictal activity. (D) Patient 4: 
Right parieto-occipital (red arrowhead), right temporal (red arrow) and left temporo-occipital 
(black arrow) ictal activity. 
Figure 2: Brain MRI of the four patients included in the study. Patient 1: Axial T2 (A), 
sagittal T1 (B) and coronal T2 (C) sequences showing cerebral atrophy with ventricular 
dilatation, thin corpus callosum, brainstem and cerebellar atrophy. Patient 2: Axial T2 (D), 
sagittal T1 (E) and coronal T2 (F) sequences showing cerebral atrophy with ventricular 
dilatation and cerebellar atrophy. Patient 3: Axial Flair (G), sagittal T1 (H) and coronal T2 (I) 
sequences showing severe cerebral atrophy with thin corpus callosum, brainstem and 
cerebellar atrophy. Patient 4: Axial  (J) and sagittal  (K) T2 and coronal (L) T1 sequences 
showing cerebral and cerebellar atrophy and a thin corpus callosum. 
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